Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
NCT ID: NCT06262399
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
100 participants
OBSERVATIONAL
2024-04-12
2040-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
NCT05120830
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
NCT04739059
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
NCT05819775
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
NCT04130191
Berotralstat Treatment in Children With Hereditary Angioedema
NCT05453968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A subject has provided informed consent for the LTFU study.
3. A subject is willing to attend study visits, complete protocol-required follow-up schedule, and comply with the study requirements.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intellia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Centre National de Reference - Grenoble
Grenoble, , France
Hôpital Claude Huriez
Lille, , France
Charite-Universitätsmedizin Berlin
Berlin, , Germany
University of Amsterdam Academic Medical Center
Amsterdam, , Netherlands
New Zealand Clinical Research
Auckland, , New Zealand
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003778-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ITL-2002-CL-999
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.